We can't find the internet
Attempting to reconnect
14446.1 PFLS-LS
Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment
Résumé
Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment
Textes supplémentaires
Abstract
Tumor cells escape poor oxygenation (hypoxia) by overexpression of Carbonic Anhydrases (CA), in particular CAIX and CAXII, which leads to a growth advantage with|increased metastasis formation and poor patient survival. siRNA targeting of both CA proteins reduces tumor growth in animal models but is hardly applicable in the clinic due to unfavourable in vivo PK/PD properties. As a novel therapeutic approach, we will generate fully human CAIX and CAXII inhibiting antibodies and combine them in a new bi-specific antibody format to target both CAs simultaneously.
Participants
Marc van Dijk
Wirtschaftspartner
4-Antibody AG Pharmazentrum Marc van Dijk Hochbergerstrasse 60c 4057 Basel BS CH
Christoph Renner
Kontaktperson
christoph.renner@unibas.ch
Universitätsspital Basel Christoph Renner Spitalstrasse 21 / Petersgraben 4 4031 Basel BS CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2013-06-30
- Date de fin
- 2015-12-31
- Coûts totaux approuvés
- CHF 371058.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%